129 results about "Dexamethasone" patented technology

The invention belongs to the technical field of plant genetic engineering, and particularly relates to an SCRE10 gene for improving rice disease resistance and application of the SCRE10 gene, the base sequence of the SCRE10 gene is shown as SEQ ID NO.1, and the amino acid sequence of the SCRE10 gene is shown as SEQ ID NO.2. Through construction of a dexamethasone induced expression SCRE10 transgenic rice plant, it is found that the transgenic rice can significantly induce PR gene expression and active oxygen outbreak, and the resistance of rice to false smut and bacterial leaf blight can be improved. The invention proves that heterologous inducible expression of the Ustilaginoidea virens SCRE10 gene has the function of positively regulating the disease resistance of the rice, and the SCRE10 gene can be used for improving the disease resistance of the rice, which is of great significance to the creation of disease-resistant germplasm of the rice.

The invention provides application of lactobacillus plantarum Lp-G18 in preparation of a medicine for preventing and / or treating skeletal muscle atrophy, and belongs to the technical field of biological medicines. The invention further provides a preparation method of the lactobacillus plantarum Lp-G18 for preventing and / or treating skeletal muscle atrophy. According to the invention, a dexamethasone (DEX)-induced C2C12 amyotrophy cell model is taken as an experimental subject to evaluate the efficacy of the phytobacterium plantarum strain Lp-G18 in the aspect of skeletal amyotrophy treatment, and the phytobacterium plantarum strain Lp-G18 has a remarkable improvement effect on DEX-induced myotube diameter reduction, fusion index reduction, protein content reduction and myotube length shortening. Therefore, the lactobacillus plantarum strain Lp-G18 can be applied to prevention and / or treatment of skeletal muscle atrophy and can be used as an active component to develop and prepare related medicines.

The invention belongs to the technical field of cell biology, and particularly discloses a culture medium and a culture method of fish primary liver cells. The culture medium of the fish primary liver cells comprises the following components: 90% of an M199 culture medium, 10% of fetal calf serum, 100 U / mL of penicillin, 0.1 mg / mL of streptomycin, 5 ng / mL of EGF, 10 [mu] U / ml of insulin and 10 mM of dexamethasone. Based on the culture medium, an efficient and stable fish liver cell culture method is developed by combining a standardized anesthesia and disinfection process, a precise dissection and liver sampling method, an optimized tissue digestion and cell separation scheme, an efficient cell purification and adherent culture system, a stable passage technology and the like; a standardized hepatocyte line establishment operation process is defined, and the problems that species binding exists in an existing fish liver cell culture method, and a standardized culture process suitable for multiple fish fingerlings is difficult to form are solved.

The invention discloses a culture medium for adipose-derived stem cells, and particularly relates to the technical field of stem cell culture. The culture medium comprises a basic culture medium and nerve-vascular niche components, wherein the basic culture medium comprises DMEM / F12, 10% of human-derived platelet lysate and 1% of antibiotic solution; the nerve-vascular niche comprises the following components: a Slit3 recombinant protein, a nerve growth factor-beta, a glial cell-derived neurotrophic factor, a lysyl oxidase inhibitor, dexamethasone, 3-isobutyl-1-methylxanthine and insulin. The traditional fetal calf serum is replaced by the human-derived platelet lysate, so that the risks of immunological rejection and pathogen pollution are avoided; through the synergistic effect of nerve-vessel niche factors, blood vessel maturation and innervation are promoted, programmed mechanical stretching culture is combined, the adipogenic differentiation efficiency of adipose-derived stem cells is remarkably improved, and engineered adipose tissue which is huge in lipid droplet, compact in structure and provided with a nerve-vessel network is formed.

The invention discloses a hexapeptide LR6 with anti-inflammatory activity and a preparation method and application thereof, and belongs to the technical field of small molecule peptides. The amino acid sequence of the hexapeptide LR6 is LDAVDR, and the hexapeptide LR6 can be prepared through a solid-phase synthesis method and an enzymolysis method. The hexapeptide LR6 is identified from spirulina platensis proteolysis liquid and has potential interaction with Keap1, an LPS-induced RAW264.7 cell test shows that TNF-alpha, IL-1beta and IL-10 can be remarkably inhibited by treatment of low-dose (200mM) and high-dose (400mM) hexapeptide LR6, the inhibition effect of the high-dose hexapeptide LR6 is superior to that of positive control dexamethasone, and the inhibition effect of the high-dose hexapeptide LR6 is superior to that of positive control dexamethasone. Compared with dexamethasone, the hexapeptide LR6 has a better anti-inflammatory effect and can be used for preparing anti-inflammatory drugs.

It was confirmed that probiotic metabolites of the present invention protect muscle cells and promote differentiation of muscle fibers. In addition, it was confirmed in an animal model of muscle atrophy or sarcopenia induced by dexamethasone that probiotic metabolites increased muscle mass and muscle function, inhibited expression of factors associated with muscle degradation, and increased expression of factors associated with muscle synthesis and regeneration. It was confirmed that probiotic metabolites contribute to alleviation of muscle atrophy by regulating sugar, amino acid, and fatty acid metabolism altered by dexamethasone.

Pharmaceutical compositions, methods for treating various issues of the eyes, and methods of preparing such compositions are described. These pharmaceutical compositions may be for treating glaucoma, in preparation of eye surgery, during eye surgery, various post-op care (e.g., after cataract surgery, laser eye surgery, and the like), for treating dry eyes, and / or for promoting eyelash growth. These pharmaceutical compositions may comprise such active ingredients (APIs) as: timolol, latanoprost, brimonidine tartrate, dorzolamide, moxifloxacin HCl, dexamethasone PO4, phenylephrine HCl, lidocaine HCl, ketorolac tromethamine, bromfenac, prednisolone PO4, gatifloxacin, amniotic cytokine extract (ACE), prostaglandin E2 (PGE2), and combinations thereof.

A lipid nanoparticle composition for use in the delivery of a self-amplifying RNA (saRNA) construct in one or more target cells is disclosed. The lipid nanoparticle composition comprises a lipid mixture comprising at least one (ionizable) cationic lipid, at least one helper lipid, a sterol, a corticosteroid such as Dexamethasone, and a least one lipid-polyethylene glycol conjugate. The saRNA construct comprises a first open reading frame which encodes one or more non-structural proteins, and a second open reading frame operatively linked to the first open reading frame. The second open reading frame comprises a coding region which encodes one or more target proteins. In some embodiments, the target proteins comprise one or more therapeutic proteins. In some embodiments, the target proteins comprise one or more one or more Cas proteins and / or variants thereof for use in CRISPR-based gene editing.

The invention belongs to the technical field of biological medicine research, and particularly relates to a cell in-vitro calcification inducer, an induction culture medium and application thereof, an aortic valve calcification in-vitro induction model and a modeling method thereof. The inducer provided by the invention is prepared from the following components in parts by weight: 2160.4 parts of beta-sodium glycerophosphate, 0.039 parts of dexamethasone, 50 parts of vitamin C and 34 parts of vitamin D. The invention further provides a culture medium formed by using the inducer and a method for modeling an aortic valve calcification in-vitro induction model by using the inducer. According to the method, osteogenic differentiation of the aortic valve interstitial cells can be stably induced within a short time, an efficient and repeatable standardized induction scheme is provided for in-vitro aortic valve calcification models and drug screening, and the method has a very good application prospect.

The invention relates to an application of Quercetin (QUE) or a derivative thereof in a medicine for resisting vocal cord fibrosis and a preparation of the Quercetin or the derivative thereof. The quercetin can significantly inhibit abnormal deposition of extracellular matrix (ECM) after vocal cord injury, improve reduction of hyaluronic acid (HA) and elastic fibers (EF), and reduce overexpression of type I collagen (COL1A1) and fibronectin (FN1). Besides, by regulating PI3K / AKT and MAPK signal channels, the quercetin inhibits proliferation and migration of fibroblasts and promotes apoptosis of the fibroblasts, so that vocal cord fibrosis is effectively relieved. The invention also provides an application of a preparation of the quercetin and the derivative thereof combined or not combined with other anti-fibrosis drugs (such as 5-fluorouracil and dexamethasone) in treatment of vocal cord fibrosis, wherein the dosage forms of the preparation comprise an oral preparation, an injection, a spray or a local gel preparation.

The present invention provides methods for treating multiple myeloma (e.g., refractory multiple myeloma or recurrent and refractory multiple myeloma) in an individual who has received at least two prior therapies for multiple myeloma. The methods comprise administering to the individual an anti-CD38 antibody, pomalidomide, and dexamethasone. Methods of ameliorating renal damage in an individual having multiple myeloma are also provided.

The present invention relates to a composition for strengthening muscle strength or preventing, ameliorating or treating muscle loss, comprising a Lilium lancifolium extract as an active ingredient. Specifically, when C2C12 cells were pre-treated with a Lilium lancifolium extract, and then treated with H2O2, dexamethasone, or TNF-α, muscle damage was alleviated and muscle loss was inhibited, and the muscle mass and grip strength decreased by dexamethasone administration in a muscle atrophy mouse model were increased upon administration of the Lilium lancifolium extract. Therefore, the composition can be effectively used as a health functional food, medicine or feed additive for strengthening muscle strength or preventing, ameliorating or treating muscle loss.

The invention discloses an application of an exocarpium citri grandis extract in preparation of an anti-pulmonary nodule product. The research finds that the iconography characteristic (CT value) of pulmonary nodules cannot be effectively improved by purely inhibiting inflammation (the effect of dexamethasone) for the first time, but the exocarpium citri grandis aqueous extract shows a remarkable nodule improving effect. It is prompted that exocarpium citri grandis can act on MWCNTs-induced pulmonary nodules through multiple targets to inhibit development of the pulmonary nodules, and the exocarpium citri grandis is expected to be used for preparing the medicine for resisting occurrence and development of the pulmonary nodules. Compared with the prior art, the exocarpium citri grandis extract disclosed by the invention is simple in preparation method and low in cost, is a natural plant extract, and can be used as a prevention health-care food or a treatment medicine. The invention not only provides a new direction for the treatment of pulmonary nodules, but also widens the application range of exocarpium citri grandis, and reveals that exocarpium citri grandis shows a wide application prospect in the aspects of maintaining human health and preventing lung cancer.

The invention relates to the technical field of pharmaceutical preparations, and provides sodium hyaluronate-dexamethasone nanoparticles as well as a preparation method and application thereof. The method comprises the following steps: dissolving dexamethasone in ethanol to obtain a dexamethasone-ethanol solution, dissolving sodium hyaluronate in an aqueous solvent to obtain a sodium hyaluronate aqueous solution, and preheating the sodium hyaluronate aqueous solution; then synchronously injecting the dexamethasone-ethanol solution serving as a lipid phase and the preheated sodium hyaluronate aqueous solution serving as a water phase into a microfluidic mixing channel at a set total flow velocity and a flow velocity ratio of the lipid phase to the water phase by adopting a microfluidic synthesis device, and forming a sodium hyaluronate-dexamethasone nanoparticle dispersion liquid in situ in the channel; and if necessary, further dispersing in a phosphate buffer solution. The obtained nanoparticles have the advantages of small particle size, good dispersity, high stability, convenience in surface modification and the like, and can be used for preparing medicines for preventing or treating inflammatory diseases.

The invention relates to the field of organ transplantation in biomedical technology, and particularly discloses normal-temperature perfusion protection liquid for thoracoscopic surgery training as well as a preparation method and application of the normal-temperature perfusion protection liquid. The components of the perfusion protection liquid mainly cover sodium chloride, carbohydrates, adenosine and dexamethasone. The perfusion protection liquid has the advantages that on one hand, the components of the protection liquid are simple, complex components of a traditional perfusion protection liquid are abandoned, and the raw material obtaining and economic cost is greatly reduced; and on the other hand, the perfusion protection liquid gets rid of the limitation of low-temperature storage and can be stably stored in a normal-temperature environment. Compared with the prior art, the perfusion protection liquid provided by the invention not only has simple components, but also breaks the constraint of cold chain transportation and low-temperature storage, solves the problems of complex components and harsh storage conditions of the existing protection liquid, provides a more convenient and efficient solution for thoracoscopic surgery training and even wider medical practice, and has broad application prospects. The method has a wide application prospect and an extremely high practical value.

The utility model relates to the field of dexamethasone production, in particular to a crystallization device for dexamethasone production, which comprises a treatment box, the device further comprises an L-shaped plate, a filter plate, a through groove, a baffle, a rotating shaft, a crystallization plate, a temperature control plate, a drainage groove, a sliding assembly, a mounting bracket, a water pump, a spray head, a guide pipe and a suction head; the treatment box is arranged, the liquid medicine is added into the treatment box, the water pump conveys the liquid medicine to the position of the spray head through the suction head and the guide pipe during operation, the liquid medicine falls on the surface of the crystallization plate in a dripping mode, and the temperature control plate can adjust the temperature of the crystallization plate so that the crystallization plate can be kept at the crystallization temperature. Due to the arrangement of the drainage groove, the flowing uniformity of the liquid medicine can be improved, part of the liquid medicine can be crystallized and left on the surface of the temperature control plate in the flowing process, the uncrystallized liquid medicine flows back to the bottom of the treatment box again after being filtered by the filter plate, and then is circulated through the water pump, so that circulating crystallization of the dexamethasone liquid medicine is realized, and the crystallization quality is improved.

This invention discloses an isoflavone compound, its preparation method, and its applications. The compounds are derived by directional esterification modification of all phenolic hydroxyl groups with allyloxycarbonyl chloride, o-chlorobenzoyl chloride, or cinnamoyl chloride, using 4',7-dihydroxyisoflavone or 4',5,7-trihydroxyisoflavone as the parent nucleus. The invention also provides a mild and efficient preparation method for these compounds and confirms their significant anti-inflammatory pharmacological activity. Pharmacological studies show that compounds B and E, in particular, exhibit excellent in vitro and in vivo anti-inflammatory activity, with compound E showing superior activity compared to the positive control drug dexamethasone. These compounds can be used to prepare drugs for treating inflammatory diseases such as pneumonia and colitis.

This invention discloses a method for inducing pluripotent stem cells to differentiate into skin keratinocytes and its culture medium, solving problems such as long differentiation cycles, low yields, insufficient purity, and animal-derived contamination in existing technologies. The first stage uses medium I containing FGF2 and tanshinone IIA to promote mesodermal differentiation. The second stage uses medium II containing BMP4, EGF, dexamethasone, and PVA to regulate and synergistically induce the BMP / ERK signaling pathway. The final stage uses medium III for expansion culture, obtaining fibroblasts with a purity >99% within 20 days. This method is non-invasive, simple, and low-cost, with potential for large-scale production. The obtained cells can be used for skin regeneration, disease modeling, drug screening, and clinical treatment, demonstrating significant medical application and industrial transformation value.

The disclosure features polymorphs of a prodrug dimer of dexamethasone linked at the 21-C and 21′-C carbons via a carbonate-triethylene glycol-carbonate linker. Also disclosed are pharmaceutical compositions and articles comprising said polymorphs, and the use thereof in the treatment of a disease or condition, e.g. via the extended or controlled release of dexamethasone from said articles.

The invention specifically discloses a novel chalcone compound as well as a preparation method, a pharmaceutical composition and application thereof. Experimental results show that the compound shows remarkable anti-inflammatory activity in a lipopolysaccharide stimulated RAW 264.7 cell model, and the anti-inflammatory activity is obviously superior to that of a positive drug dexamethasone; the compound shows a remarkable lipid accumulation inhibition effect in a HepG2 cell model treated by free fatty acid, is obviously superior to a positive drug obeticholic acid, and can be used for developing drugs for treating the non-alcoholic fatty liver disease, including but not limited to simple fatty liver, non-alcoholic steatohepatitis and related liver cirrhosis.

The invention discloses a film-covered balloon double-cavity stomach tube and a preparation method thereof. The stomach tube comprises a double-cavity stomach tube body, a compliance balloon and a drug-loaded fiber film. The double-cavity stomach tube is provided with a main cavity for gastrointestinal drainage and a side cavity for balloon inflation and deflation; the compliance balloon is fixed to the esophageal section and expands and contracts through inflation and deflation of a side cavity. The outer surface of the balloon is coated with the drug-loaded fiber covering film, the drug-loaded fiber covering film is composed of coaxial drug-loaded nanofibers, a sheath layer of the drug-loaded fiber covering film is made of a blend of polylactic acid caprolactone and collagen, and a core layer of the drug-loaded fiber covering film is made of polylactic acid caprolactone dispersed with anti-inflammatory drugs and local anesthetic drugs. According to the preparation method, a drug-loaded fiber covering film is constructed on the surface of the balloon through a coaxial electrostatic spinning technology, drugs (such as dexamethasone and lidocaine) can be encapsulated in a nanofiber core layer, a sheath polymer material is used as a diffusion barrier, burst release of the drugs is effectively prevented, continuous and controllable release of the drugs at the esophageal diseased region is achieved, and the drug delivery effect is improved. The medicine action time is obviously prolonged; the curative effect is improved.

The invention relates to a construction method of a peripheral red blood cell humanized mouse, which comprises the following steps: transplanting human hematopoietic stem cells into the mouse and then applying a red blood cell inducer to the mouse, or applying a red blood cell inducer to the mouse and then infusing human red blood cells into the mouse. The red blood cell inducer comprises an antibody targeting mouse macrophage, dexamethasone or a derivative thereof, and a human macrophage colony stimulating factor. In a mouse transplanted with human hematopoietic stem cells, one or more of an antibody targeting mouse macrophages, dexamethasone and a human macrophage colony stimulating factor can be used in the red blood cell induced maturation process, and high-level human red blood cell reconstruction can be quickly realized within three weeks; the maturity and the denucleation ratio of peripheral human erythrocytes reconstructed in the mouse are completely consistent with those of normal human blood; in a mouse transplanted with human erythrocytes, the erythrocyte induction process can be single treatment of an antibody or dexamethasone, or combined use of the antibody and dexamethasone. The invention also provides application of the peripheral erythrocyte humanized mouse.

The invention aims to provide a preparation method and application of a gouty arthritis microenvironment response type diagnosis and treatment integrated nanoprobe, and belongs to the technical field of biomedical nanomaterials. Natural tea extract tea polyphenol is used as a raw material, polyoxyethylene-polyoxypropylene-polyoxyethylene copolymer is used as a template, a soft template method is utilized, and the gouty arthritis microenvironment response type diagnosis and treatment integrated nanoprobe is prepared. And stirring, centrifuging and freeze-drying to synthesize the mesoporous tea polyphenol nano-particles. Meanwhile, indocyanine green with fluorescence emission in a near-infrared second region and a steroid anti-inflammatory drug dexamethasone are connected to the two ends of an active oxygen response type ketal thiol bond respectively, and the active oxygen response type nano-particles are synthesized through stirring, dialysis and freeze drying. And finally, loading the response type nano-particles in mesoporous tea polyphenol by a solvent impregnation method to realize anti-inflammatory and anti-oxidation treatment of gouty arthritis at different stages.

The invention belongs to the technical field of biomedicine, and discloses an antibody for evaluating the curative effect of infantile pneumonia asthma and application of the antibody. The heavy chain CDR sequence of the monoclonal antibody (secreted by the hybridoma cell strain 2B5) is SEQ ID NO: 2-4, the light chain CDR sequence of the monoclonal antibody (secreted by the hybridoma cell strain 2B5) is SEQ ID NO: 6-8, the dissociation constant of the monoclonal antibody and an IL-5R antigen reaches 2.435 * 10 <-1 > / L, and the affinity is high. The antibody can accurately evaluate the curative effect of infantile pneumonia and asthma by detecting the lung function, the ratio of eosinophilic granulocytes in bronchoalveolar lavage fluid and lung tissue inflammation, can also significantly improve airway obstruction and inflammation of asthma model mice, has an effect superior to that of dexamethasone, solves the problems that existing curative effect evaluation is lack of specific tools and has large side effects of therapeutic drugs, and has good clinical application prospects. And a new scheme is provided for curative effect evaluation and adjuvant therapy of infantile pneumonia asthma.

This invention discloses the application of agar-agar polysaccharides in the preparation of products with bone density-improving effects. The agar-agar polysaccharides are obtained from agar-agar as raw material through acid extraction, alcohol precipitation, dialysis, and ion exchange chromatography purification, with a weight-average molecular weight range of 1500-5000 Da. This invention applies agar-agar polysaccharides to the preparation of products with bone density-improving effects, including food, health products, or pharmaceuticals; particularly, it can be used to prepare functional cereal foods. The agar-agar polysaccharides of this invention have an ameliorative effect on bone density loss in a dexamethasone-induced zebrafish osteoporosis model, can enhance the activity of alkaline phosphatase (ALP) in zebrafish, and promote osteoblast differentiation.

The present invention discloses an ophthalmic composition comprising dexamethasone or its pharmaceutically acceptable salt thereof and that is used to treat cataract surgery pain and diabetic macular edema. The present invention relates to use of a topically administrate ophthalmic suspension composition of dexamethasone, or it pharmaceutically acceptable salt thereof suspended in pharmaceutically acceptable vehicle, wherein the pharmaceutical acceptable vehicle comprises at least one excipient selected from suspending agent, tonicity agent, antimicrobial agent, buffering agent, chelating agent, antioxidant, surface active agent, and pH adjusting agent.

The invention discloses an induction culture medium with definite components and application of the induction culture medium in preparation of a hepatic fibrosis treatment medium, and belongs to the technical field of hepatic cell culture and artificial liver. The induction culture medium is composed of a serum-free basic culture medium, primary bile acid and secondary bile acid, the serum-free basic culture medium is composed of a William's E culture medium, penicillin, streptomycin, L-glutamine, insulin, transferrin, sodium selenite and dexamethasone, the primary bile acid is an FXR signal channel stimulant, and the secondary bile acid is a TGR signal channel stimulant. The hepatic fibrosis treatment medium prepared by utilizing the induction culture medium has a remarkable hepatic fibrosis relieving effect, and has the advantages of definite production materials, controllable process, high product stability and the like.

The invention provides a structure, preparation and application of a supramolecular hydrogel which is formed by self-assembly of two single components, namely alpha-D-pentagalloylgalactose and alpha-D-pentagalloylmannose, in water under the condition of not being subjected to any structural modification and pretreatment, as well as a preparation method and application of the supramolecular hydrogel. According to the alpha-D-pentagalloyl galactose and alpha-D-pentagalloyl mannose supramolecular hydrogel, the hydrogel can be formed under the condition that no gelator is used, and the hydrogel has excellent gel properties such as injectability, heat sensitivity, self-healing property and stability. Meanwhile, the two supramolecular hydrogels both have good immunoregulation, anti-inflammatory and antioxidant activities, are both superior to clinical first-line drugs (dexamethasone and ascorbic acid), and also show good angiogenesis promoting ability. A large number of tests show that the supramolecular hydrogel has good biological safety, and clinical medication safety can be further guaranteed.

Provided herein are methods of treating and / or managing cancer, comprising administering to a patient Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof. Additionally, provided herein are methods of treating and / or managing cancer, comprising administering to a patient Compound A, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, in combination with a second active agent selected from the group consisting of an anti-CD20 antibody, an HDAC inhibitor, a proteasome inhibitor, an anti-CD38 antibody, an anti-SLAMF7 antibody, a nuclear export inhibitor, a BCL-2 inhibitor, and an immune checkpoint inhibitor. Also provided herein are combination therapies for treating and / or managing cancer, further comprising dexamethasone as a third active agent.